Phase I
Ultragenyx Pharmaceutical Inc. announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for the treatment of glycogen storage disease type Ia.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform inhibitor, in patients with relapsed or refractory lymphoma.
Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action
Successful validation of standardized clinical procedure for instillation of nanoparticles in first patient cohort
This study aimed to determine the appropriate dose for Japanese patients treated with lurbinectedin, in monotherapy, for advanced solid tumors.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
MyoKardia, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy.
Forendo Pharma announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
PRESS RELEASES